Literature DB >> 12586469

Molecular monitoring in malaria vaccine trials.

Ingrid Felger1, Blaise Genton, Tom Smith, Marcel Tanner, Hans Peter Beck.   

Abstract

Molecular techniques offer new approaches for malaria field trials, particularly PCR techniques, which facilitate accurate diagnosis of Plasmodium infections and increase the power of estimates of vaccine effects on malaria prevalence or incidence. Molecular methods also help to assess selective effects of vaccines. Longitudinal genotyping data can be used to initiate novel analyses of parasite dynamics, including estimates of incidence of infection with individual parasite clones and duration of infections. In addition, high-throughput methods can be used to apply these techniques routinely in randomized controlled trials, as well as programme-based evaluations of malaria control.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12586469     DOI: 10.1016/s1471-4922(02)00066-1

Source DB:  PubMed          Journal:  Trends Parasitol        ISSN: 1471-4922


  13 in total

1.  Force of infection is key to understanding the epidemiology of Plasmodium falciparum malaria in Papua New Guinean children.

Authors:  Ivo Mueller; Sonja Schoepflin; Thomas A Smith; Kathryn L Benton; Michael T Bretscher; Enmoore Lin; Benson Kiniboro; Peter A Zimmerman; Terence P Speed; Peter Siba; Ingrid Felger
Journal:  Proc Natl Acad Sci U S A       Date:  2012-06-04       Impact factor: 11.205

2.  High-throughput pooling and real-time PCR-based strategy for malaria detection.

Authors:  Steve M Taylor; Jonathan J Juliano; Paul A Trottman; Jennifer B Griffin; Sarah H Landis; Paluku Kitsa; Antoinette K Tshefu; Steven R Meshnick
Journal:  J Clin Microbiol       Date:  2009-11-25       Impact factor: 5.948

3.  Study of parasite kinetics with antileishmanial drugs using real-time quantitative PCR in Indian visceral leishmaniasis.

Authors:  Medhavi Sudarshan; Jason L Weirather; Mary E Wilson; Shyam Sundar
Journal:  J Antimicrob Chemother       Date:  2011-05-24       Impact factor: 5.790

Review 4.  Experimental human challenge infections can accelerate clinical malaria vaccine development.

Authors:  Robert W Sauerwein; Meta Roestenberg; Vasee S Moorthy
Journal:  Nat Rev Immunol       Date:  2011-01       Impact factor: 53.106

Review 5.  Measuring changes in Plasmodium falciparum transmission: precision, accuracy and costs of metrics.

Authors:  Lucy S Tusting; Teun Bousema; David L Smith; Chris Drakeley
Journal:  Adv Parasitol       Date:  2014       Impact factor: 3.870

6.  Strain-specific humoral response to a polymorphic malaria vaccine.

Authors:  Christian Flück; Tom Smith; Hans-Peter Beck; Andrea Irion; Inoni Betuela; Michael P Alpers; Robin Anders; Allan Saul; Blaise Genton; Ingrid Felger
Journal:  Infect Immun       Date:  2004-11       Impact factor: 3.441

7.  Diagnosing infection levels of four human malaria parasite species by a polymerase chain reaction/ligase detection reaction fluorescent microsphere-based assay.

Authors:  David T McNamara; Laurin J Kasehagen; Brian T Grimberg; Jennifer Cole-Tobian; William E Collins; Peter A Zimmerman
Journal:  Am J Trop Med Hyg       Date:  2006-03       Impact factor: 2.345

8.  Estimating Plasmodium falciparum transmission rates in low-endemic settings using a combination of community prevalence and health facility data.

Authors:  Joshua Yukich; Olivier Briët; Michael T Bretscher; Adam Bennett; Seblewengel Lemma; Yemane Berhane; Thomas P Eisele; Joseph Keating; Thomas Smith
Journal:  PLoS One       Date:  2012-08-22       Impact factor: 3.240

9.  Real-time PCR detection of Plasmodium directly from whole blood and filter paper samples.

Authors:  Brian J Taylor; Kimberly A Martin; Eliana Arango; Olga M Agudelo; Amanda Maestre; Stephanie K Yanow
Journal:  Malar J       Date:  2011-08-19       Impact factor: 2.979

10.  Comparison of clinical and parasitological data from controlled human malaria infection trials.

Authors:  Meta Roestenberg; Geraldine A O'Hara; Christopher J A Duncan; Judith E Epstein; Nick J Edwards; Anja Scholzen; André J A M van der Ven; Cornelus C Hermsen; Adrian V S Hill; Robert W Sauerwein
Journal:  PLoS One       Date:  2012-06-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.